Oncolytics Biotech

📊 Rating

2 news mentions · 👍 0 likes · 👎 0 dislikes

📌 Topics

Financial Analysis (1)
Biotechnology (1)
Investing (1)
Corporate Disclosure (1)
Regulatory Filing (1)

🏷️ Keywords

Oncolytics Biotech (2) · H.C. Wainwright (1) · Buy rating (1) · stock analysis (1) · biotechnology investment (1) · Form 8-K (1) · SEC filing (1) · material event (1) · March 20 (1)

📖 Key Information

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

📰 Related News (2)

🇺🇸 H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy (2026-04-10)
🇺🇸 Form 8K Oncolytics Biotech Inc. For: 20 March (2026-03-20)

🔗 Entity Intersection Graph

People and organizations frequently mentioned alongside Oncolytics Biotech:

SEC filing · 1 shared articles